What it sells
Unlocking the next generation of mRNA medicines
Business model breakdown
Workflow: what inputs become what output?
Cell-based mRNA design and manufacturing platform (vector platform: design, engineer, extract, output) replacing cell-free in vitro transcription.
Economics: what it saves and how it charges
UnverifiedPre-revenue biotech; press cites a $47M raise to expand the platform; likely partnership/licensing returns (inferred).
Distribution: how it reaches customers
Partnerships ("Speak with us").
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.